Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective

被引：0
|
作者：
Sofrygin, O.
Delea, T. E.
Tappenden, P.
Karnon, J.
Browning, D.
Amonkar, M.
Lykopoulos, K.
Cameron, D. A.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[3] Univ Adelaide, Dept Publ Hlth, Adelaide, SA, Australia
[4] GlaxoSmithKline Hlth Outcomes Oncol, London, England
[5] GlaxoSmithKline, Collegeville, PA USA
[6] GlaxoSmithKline Global Hlth Outcomes, London, England
[7] Univ Edinburgh, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective
    Delea, T. E.
    Tappenden, P.
    Sofrygin, O.
    Karnon, J.
    Amonkar, M.
    Browning, D.
    Rudge, H.
    Walker, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 225 - 225
  • [2] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+metastatic breast cancer who have received prior therapy with trastuzumab
    Delea, Thomas E.
    Tappenden, Paul
    Sofrygin, Oleg
    Browning, Dominy
    Amonkar, Mayur M.
    Karnon, Jon
    Walker, Mel D.
    Cameron, David
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (05): : 589 - 603
  • [3] Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
    Thomas E. Delea
    Paul Tappenden
    Oleg Sofrygin
    Dominy Browning
    Mayur M. Amonkar
    Jon Karnon
    Mel D. Walker
    David Cameron
    The European Journal of Health Economics, 2012, 13 : 589 - 603
  • [4] Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with HER2+metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151
    DeLea, T.
    Tappenden, P.
    Sofrygin, O.
    Karnon, J.
    Amonkar, M.
    Browning, D.
    Rudge, H. J.
    Walker, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
    Wu, Yue
    Dong, Zhu
    Wang, Jiangfeng
    Fang, Qingxia
    BMJ OPEN, 2022, 12 (11):
  • [6] Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective
    Hastings, V.
    Delea, T. E.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J.
    Johnston, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
    Bao, Yuwen
    Zhang, Zhuolin
    He, Xuan
    Cai, Lele
    Wang, Xiao
    Li, Xin
    CURRENT ONCOLOGY, 2022, 29 (09) : 6053 - 6067
  • [8] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
  • [9] COST-UTILITY MODEL OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRASTUZUMAB AND A TAXANE, COMPARED WITH CAPECITABINE PLUS LAPATINIB, TRASTUZUMAB PLUS CAPECITABINE AND CAPECITABINE ALONE IN TURKEY
    Akyol Ersoy, B.
    Erdogan-Ciftci, E.
    Yanik, L.
    Guler, B.
    Ozcan, G.
    Paracha, N.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [10] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
12345